11 August 2021 : Clinical Research
Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center
Jianquan Zhu1ABCDEF, Yu Zhang1BC, Meng Wang1BC, Zhenfa Zhang1BC, Dongsheng Yue1BC, Shichang Liu2BC, Yi Pan3BC, Changli Wang1AE*DOI: 10.12659/MSM.930738
Med Sci Monit 2021; 27:e930738
Table 1 Baseline characteristics of patients with squamous cell carcinoma of the lung.
| Characteristics | ITT (n=36) | Surgery (n=23) |
|---|---|---|
| Age (years), median (range) | 58 (45–76) | 58 (45–63) |
| Male, (%) | 36 (100) | 23 (100) |
| Smoking, (%) | ||
| Never | 5 (13.9) | 4 (17.4) |
| Former/current | 31 (86.1) | 19 (82.6) |
| ECOG performance status, (%) | ||
| 0 | 17 (47.2) | 13 (56.5) |
| 1 | 19 (52.8) | 10 (43.5) |
| T stage, (%) | ||
| T2 | 23 (63.9) | 14 (60.9) |
| T3 | 13 (36.1) | 9 (39.1) |
| ECOG – Eastern Cooperative Oncology Group; ITT – intention-to-treat. | ||